跳至主要内容

Medicilon appointed Dr. Rui Zhang as Senior VP of Pharmaceutical Research

 Recently, Shanghai Medicilon Inc. (hereinafter referred to as "Medicilon") appointed Dr. Rui Zhang as Senior Vice President of Pharmaceutical Research.

After this appointment, Dr. Zhang will further promote Medicilon to enter the CDMO field, help Medicilon to establish a large-scale production base in line with GMP standards through strategic cooperation, self-construction or merger and acquisition, further improve the crystal research service platform, strengthen the construction of technical platform in the field of small nucleic acid drugs and polypeptide drug preparations, and help Medicilon achieve "CRO+CDMO" two-wheel drive. At the same time, Dr. Zhang will also further promote the business development of Medicilon and help Medicilon to research and develop new drugs.

Dr. Rui Zhang.jpg

Dr. Rui Zhang, Ph.D., University of Victoria, Postdoc at the School of Pharmacy, University of Manitoba, has been deeply involved in the field of drug research and development for 15 years. He has led the development of 6 small molecule PCC drugs and successfully pushed several small molecule new drug projects to the clinical stage. He has completed a number of NDA, IND, PLGA excipient applications, has been responsible for a number of new drug CMC work, and developed a number of international and domestic leading process projects. Dr. Rui Zhang has extensive experience in the whole-process development of new drugs, improved new drugs (including high-end complex preparations) and generic drugs, and will help Medicilon to empower all aspects of new drug research and development, including product development, quality research, change control, production and declaration. Dr. Zhang was selected as a talent in Sichuan's "Tianfu Emei Plan", Shandong's "Taishan Industry Leading Talent" and Yantai's "Double Hundred Plan".

Prior to joining Medicilon, Dr. Rui Zhang served as Vice President of Research and Development and head of the Chemical Department at Shandong Luye Pharma Group, where he was responsible for drug discovery, drug development, CMC and the group's chemical R&D department. Prior to this, Dr. Zhang served as Jinan Kanghe Medical Science & Technology Co., LTD., AstaTech-Chengdu, CanAm Bioressearch Inc., and CombiPhos Catalysts Inc.Senior executive, has accumulated rich experience in drug research and development practice and team management.

The Medicilon Process Department is deeply involved in the entire industrial chain system of the R&D, procurement and production, from preclinical small-scale synthesis route optimization, process development and scale-up, process validation, quality research to commercial production.

Pharmaceutical CDMO can provide clients with innovative R&D services including process chemistry, formulation and industrial production. Pharmaceutical CDMO fully integrates and deeply connects all phases of drug R&D, including the preclinical study, the clinical trials and the commercialization.

评论

此博客中的热门博文

What is preclinical testing?

In the process of  preclinical testing  of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a  preclinical research  phase followed, before which, as described above, the potential tox...

Inventory of the three major in vitro pharmacokinetic research methods

  The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d...

Enzyme Activity Assay Service

  Enzymatic assay Lance Assay Alphascreen Assay Z’-LYTE Assay Adapta Assay Kinase-Glo Assay ADP-Glo Assay Ligand Binding Assay ELISA Assay HTRF Assay Enzyme activity assays  are laboratory methods for measuring enzymatic activity. They are vital for the study of enzyme kinetics and enzyme inhibition. Enzyme units : Amounts of enzymes can either be expressed as molar amounts, as with any other chemical, or measured in terms of activity, in enzyme units. Medicilon provides various  enzyme activity assays  for  kinases , phosphatases, proteinases, deacetylase, peptidase, esterase, and other enzymes. Our line of well-characterized immunoassays and biochemical kits ensures accurate and reproducible results. Enzyme is a  large category of bio-molecules  that catalyze various biological processes including metabolic processes, cellular signaling and regulation, cell division and apoptosis. Enzymatic reactions convert substrate molecules into chemically modifi...